Anti-tumor agents have been developing every year, and the overall survival in gastrointestinal cancer patients is dramatically improved in a decade. As the duration of treatment prolongs, quality of life (QoL) and management for adverse events have become increasingly important. Diet is an important factor in QoL maintenance, but it is known that adverse events of chemotherapy include anorexia, nausea, vomiting, and dysgeusia, which can lead to reduced oral intake. The incidence of dysgeusia associated with chemotherapy is reported to be approximately 56-76%, depending on the type of chemotherapy. Prolonged dysgeusia may worsen nutritional status and performance status. Nausea and vomiting can be treated with an antiemesis, but there has been no promising intervention for dysgeusia for a long time. The mechanism of chemotherapy-induced dysgeusia is not yet clear, but it has been reported that cells with rapid turnover, such as taste bud cells, are more sensitive to chemotherapy than other cells. Furthermore, it has been demonstrated that the regeneration of taste bud cells requires large amounts of zinc. Therefore, zinc deficiency can cause dysgeusia. Cytotoxic agents may act as a chelator for zinc. However, there are no prospective multicenter studies of the effects of zinc administration on dysgeusia caused by chemotherapy. By analysing various factors related to dysgeusia due to chemotherapy, we can identify the factors associated with dysgeusia and clarify the effectiveness of zinc preparations, which will contribute to the establishment of supportive care for patients undergoing chemotherapy. Therefore, we planned a multicenter, prospective observational study on cases of dysgeusia caused by chemotherapy for gastrointestinal cancer. This study is carried out as an investigator-initiated, multicenter, prospective observational study to determine clinical or treatment factors associated with chemotherapy-related dysgeusia in patients with advanced gastrointestinal cancer. Eligibility criteria include patients presenting grade 1 or more dysgeusia in Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or Scale of Subjective Total Taste Acuity (STTA) during chemotherapy for gastrointestinal cancer. One of the important exclusion criteria is the administration of zinc preparations before presenting dysgeusia. After registration, physicians will collect clinical information related to dysgeusia prospectively for 12 weeks using blood sampling and two times questionnaires. The treatment method for dysgeusia is determined by the physician’s choice (no intervention, polaprezinc, or zinc acetate hydrate). The data to be collected in this study include changes in dysgeusia, the relationship between serum zinc levels and dysgeusia, the contribution of physical factors to dysgeusia (age, height, weight, body surface area), the involvement of nutritional factors (hemoglobin level, serum iron, albumin level) and the safety of the intervention. A total of 180 cases are planned for registration in 13 institutions. In this study, we can evaluate the effects of factors contributing to dysgeusia, and the effects of zinc preparations on improving dysgeusia. This study was approved by the institutional review board of Hokkaido University Hospital (approval number: 019-0248). Clinical trial information: UMIN000039653. We would like to express special thanks to all participating investigators. The authors.